These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 29974943)

  • 41. Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.
    Menssen AJ; Khanna A; Miller CA; Nonavinkere Srivatsan S; Chang GS; Shao J; Robinson J; O'Laughlin M; Fronick CC; Fulton RS; Brendel K; Heath SE; Saba R; Welch JS; Spencer DH; Payton JE; Westervelt P; DiPersio JF; Link DC; Schuelke MJ; Jacoby MA; Duncavage EJ; Ley TJ; Walter MJ
    Blood Cancer Discov; 2022 Jul; 3(4):330-345. PubMed ID: 35709710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
    Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
    Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.
    Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ
    Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
    Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
    Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia.
    Mori N; Hidai H; Yokota J; Okada M; Motoji T; Oshimi K; Mizoguchi H
    Leuk Res; 1995 Nov; 19(11):869-75. PubMed ID: 8551805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
    Jacoby MA; Duncavage EJ; Chang GS; Miller CA; Shao J; Elliott K; Robinson J; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Pusic I; Welch JS; Link DC; DiPersio JF; Westervelt P; Ley TJ; Graubert TA; Walter MJ
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.
    Schwind S; Jentzsch M; Kubasch AS; Metzeler KH; Platzbecker U
    Neoplasia; 2021 Nov; 23(11):1101-1109. PubMed ID: 34601234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C; Chi J; Wang L
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
    Bănescu C; Tripon F; Muntean C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
    Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
    Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies.
    Maserati E; Pressato B; Valli R; Minelli A; Sainati L; Patitucci F; Marletta C; Mastronuzzi A; Poli F; Lo Curto F; Locatelli F; Danesino C; Pasquali F
    Br J Haematol; 2009 Apr; 145(2):190-7. PubMed ID: 19222471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
    Dussiau C; Fontenay M
    Exp Hematol; 2018 Feb; 58():17-26. PubMed ID: 29175473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.
    Schratz KE; Gaysinskaya V; Cosner ZL; DeBoy EA; Xiang Z; Kasch-Semenza L; Florea L; Shah PD; Armanios M
    J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34343137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.